Thyroid hormone replacement approved as diagnostic aid
This article was originally published in Clinica
Genzyme General's Thyrogen (injectable thyrotropin alpha) has been approved in the US for use in follow-up screening of thyroid cancer patients. The drug, a recombinant form of thyroid stimulating hormone (TSH), allows patients who undergo diagnostic testing for cancer recurrence to avoid side-effects caused by the withdrawal of their hormone supplements, which accompanies testing.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.